355 related articles for article (PubMed ID: 27411688)
1. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
[TBL] [Abstract][Full Text] [Related]
2. [Epigenetic regulation of cell adhesion-mediated drug resistance acquisition in multiple myeloma].
Furukawa Y; Kikuchi J
Rinsho Ketsueki; 2016 May; 57(5):546-55. PubMed ID: 27263778
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
Kikuchi J; Koyama D; Wada T; Izumi T; Hofgaard PO; Bogen B; Furukawa Y
J Clin Invest; 2015 Oct; 125(12):4375-90. PubMed ID: 26517694
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment drug resistance in multiple myeloma: emerging new players.
Di Marzo L; Desantis V; Solimando AG; Ruggieri S; Annese T; Nico B; Fumarulo R; Vacca A; Frassanito MA
Oncotarget; 2016 Sep; 7(37):60698-60711. PubMed ID: 27474171
[TBL] [Abstract][Full Text] [Related]
6. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
7. Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells.
Xu X; He Y; Miao X; Wu Y; Han J; Wang Q; Liu J; Zhong F; Ou Y; Wang Y; He S
Leuk Res; 2016 Aug; 47():54-62. PubMed ID: 27258734
[TBL] [Abstract][Full Text] [Related]
8. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
9. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
10. Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.
Shen Y; Sun Y; Zhang L; Liu H
Tumour Biol; 2017 Jun; 39(6):1010428317703941. PubMed ID: 28653881
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Hideshima T; Richardson P; Chauhan D; Palombella VJ; Elliott PJ; Adams J; Anderson KC
Cancer Res; 2001 Apr; 61(7):3071-6. PubMed ID: 11306489
[TBL] [Abstract][Full Text] [Related]
12. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM).
Huang Y; Huang X; Cheng C; Xu X; Liu H; Yang X; Yao L; Ding Z; Tang J; He S; Wang Y
BMC Cancer; 2019 Dec; 19(1):1269. PubMed ID: 31888545
[TBL] [Abstract][Full Text] [Related]
14. [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
Kikuchi J; Furukawa Y
Nihon Rinsho; 2015 Jan; 73(1):57-61. PubMed ID: 25626305
[TBL] [Abstract][Full Text] [Related]
15. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Kikuchi S; Suzuki R; Ohguchi H; Yoshida Y; Lu D; Cottini F; Jakubikova J; Bianchi G; Harada T; Gorgun G; Tai YT; Richardson PG; Hideshima T; Anderson KC
Leukemia; 2015 Sep; 29(9):1918-27. PubMed ID: 25801913
[TBL] [Abstract][Full Text] [Related]
16. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.
Kobune M; Chiba H; Kato J; Kato K; Nakamura K; Kawano Y; Takada K; Takimoto R; Takayama T; Hamada H; Niitsu Y
Mol Cancer Ther; 2007 Jun; 6(6):1774-84. PubMed ID: 17575106
[TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of drug resistance and sensitivity concerning novel agents for multiple myeloma].
Tokuhira M
Rinsho Ketsueki; 2016 May; 57(5):563-74. PubMed ID: 27263780
[TBL] [Abstract][Full Text] [Related]
18. RBQ3 participates in multiple myeloma cell proliferation, adhesion and chemoresistance.
Liu H; Ding L; Shen Y; Zhong F; Wang Q; Xu X
Int J Biol Macromol; 2016 Oct; 91():115-22. PubMed ID: 27189701
[TBL] [Abstract][Full Text] [Related]
19. [Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells].
Zang MR; Li F; An G; Xie ZQ; Li CH; Yu Z; Xu Y; Qiu LG; Hao M
Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(16):1100-3. PubMed ID: 22781767
[TBL] [Abstract][Full Text] [Related]
20. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
Rastgoo N; Abdi J; Hou J; Chang H
J Hematol Oncol; 2017 Jun; 10(1):121. PubMed ID: 28623912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
